➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Mallinckrodt
McKinsey
Johnson and Johnson
Harvard Business School

Last Updated: October 30, 2020

DrugPatentWatch Database Preview

Exela Pharma Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for EXELA PHARMA, and what generic alternatives to EXELA PHARMA drugs are available?

EXELA PHARMA has seventeen approved drugs.

There are seven US patents protecting EXELA PHARMA drugs.

There is one patent family member on EXELA PHARMA drugs in one country and eighty-six supplementary protection certificates in nine countries.

Summary for Exela Pharma
International Patents:1
US Patents:7
Tradenames:17
Ingredients:15
NDAs:17
Patent Litigation for Exela Pharma: See patent lawsuits for Exela Pharma

Drugs and US Patents for Exela Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exela Pharma NOURESS cysteine hydrochloride SOLUTION;INTRAVENOUS 212535-001 Dec 13, 2019 DISCN Yes No 10,478,453   Start Trial Y   Start Trial
Exela Pharma NIPRIDE RTU IN SODIUM CHLORIDE 0.9% sodium nitroprusside SOLUTION;INTRAVENOUS 209387-001 Mar 8, 2017 RX Yes Yes   Start Trial   Start Trial
Exela Pharma SODIUM BICARBONATE sodium bicarbonate INJECTABLE;INJECTION 211091-001 Jun 20, 2019 AP RX No Yes   Start Trial   Start Trial
Exela Pharma AKOVAZ ephedrine sulfate SOLUTION;INTRAVENOUS 208289-001 Apr 29, 2016 AP RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Exela Pharma Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1175904 2007C/048 Belgium   Start Trial PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826
0107734 93C0042 Belgium   Start Trial PROD. NAME TETRAKIS (2-METHOXY-ISOBUTYL-ISONITRILE). CUIVRE (I) TETRAFLUOROBORATE, DIHYDRATE DE CHLORURE STANNEUX, CHLORHYDRATE DE L-CYSTEINE (MONOHYDRATE); REG NO/DATE 923 IS 3 F 12/ 19900924 ; FIRST REG CC NO DATE IE PA 200/9/1 19900817
0957929 SPC/GB06/021 United Kingdom   Start Trial PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
1912999 1490062-5 Sweden   Start Trial PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKinsey
Express Scripts
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.